TGF-β Signaling Pathway Disruption for Effective Treatment of HCC With NK Cells

Dan Kaufman, MD, PhD, professor of medicine at the University of California, San Diego, discusses recent research on transforming growth factor beta (TGF-β) and how it is linked to the development of hepatocellular carcinoma (HCC).

TGF-β inhibition works in conjunction with anti-HCC chimeric antigen receptors (CARs) to promote anti-tumor activity, and enables the expression of anti-HCC CARs on iPSC-NK cells.

00:00 TGF-β and the Development of HCC

01:28 Anti-HCC CARs and TGF-β

03:02 Efficacy of NK Cell-Based Therapies

07:54 TGF-β Inhibition With NK Cells

08:31 Challenges of T Cell and NK Cell Therapies

10:18 Future Research Directions